1. Home
  2. APPS vs CGEM Comparison

APPS vs CGEM Comparison

Compare APPS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Turbine Inc.

APPS

Digital Turbine Inc.

HOLD

Current Price

$11.80

Market Cap

1.5B

Sector

Miscellaneous

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$21.00

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPS
CGEM
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
APPS
CGEM
Price
$11.80
$21.00
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$6.25
$30.13
AVG Volume (30 Days)
2.4M
722.5K
Earning Date
06-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
62.92
N/A
EPS
N/A
N/A
Revenue
$103,569,000.00
N/A
Revenue This Year
$15.60
N/A
Revenue Next Year
$11.34
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
38.55
N/A
52 Week Low
$2.74
$5.68
52 Week High
$15.34
$23.19

Technical Indicators

Market Signals
Indicator
APPS
CGEM
Relative Strength Index (RSI) 56.13 52.22
Support Level $8.03 $11.87
Resistance Level $11.71 $23.19
Average True Range (ATR) 0.63 0.87
MACD -0.01 -0.25
Stochastic Oscillator 96.00 21.52

Price Performance

Historical Comparison
APPS
CGEM

About APPS Digital Turbine Inc.

Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: